Science 37 Holdings, Inc. (Nasdaq: SNCE) today announced new
patient relationship management and contact center technology to
improve patient engagement, leading to faster patient recruitment
and greater enrollment conversion rates.
Science 37’s new patient relationship management
platform enables significant efficiency in media planning,
placement, reporting and patient communications to yield faster,
more qualified patient recruitment for clinical trials. The
platform also is able to curate content which can be utilized to
improve engagement amongst Science 37’s existing patient
community.
After expressing interest in a study, Science 37’s
new contact center technology enables near, real-time dialog,
across a variety of communications channels, between a qualified
patient and a remote study coordinator to ensure that qualified
patients who would like to participate have every opportunity to
enroll.
“Our new investments in patient relationship
management and contact center technology enables us to
significantly improve the speed and cost to recruit patients, in
addition to our conversion rates from contact to consent,” said
Darcy Forman, Chief Delivery Officer, Science 37. “Ultimately,
we’re delivering on our mission to provide universal access to
anyone, anywhere.”
Enrolling patients in clinical research is the
primary driver for clinical trial delays which represent a
staggering 80% of all trials1. This is hardly surprising, given
that far fewer than 8% of patients have the opportunity to
participate in clinical trials2 under the traditional site-based
model that poses fundamental access challenges through its
intrinsic creation of geographic boundaries.
“While study sponsors often deploy multi-channel
approaches to drive patients from outside an investigator’s
practice into brick-and-mortar sites, traditional sites have a poor
track record in enrolling these referrals into the study because
the site’s lack the focus and processes to be successful,”
continued Ms. Forman. “The Science 37 enrollment model is fully
designed with the mindset that no patient should be left
behind.”
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 l Operating System (OS) supports
today’s more agile clinical research designs with its full-stack,
end-to-end technology platform and centralized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators, provider communities, and data and devices.
Configurable to enable almost any study type, the Science 37 OS
enables up to 21x faster enrollment, 28% better retention, and 3x
more diverse patient population with industry-leading workflow
orchestration, evidence generation, and data harmonization. For
more information, visit https://www.science37.com.
Sources1 Science 37, Brand Benchmark Survey 2022.2
Unger, J.M., Vaidya, R., Hershman, D.L., Miniasian, L.M., Fleury,
M.: “Systematic Review and Meta-Analysis of the Magnitude of
Structural, Clinical, Physician and Patient Barriers to Cancer
Clinical Trial Participation”; Journal of the National Cancer
Institute, Vol. 111, Issue 3, March 2019.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains certain forward-looking
statements within the meaning of the federal securities laws,
including statements regarding the products offered by Science 37,
its sales pipeline and the markets in which it operates. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on Nasdaq, (ii) volatility in the price of Science 37’s
securities due to a variety of factors, including changes in the
competitive and highly regulated industries in which Science 37
operates, variations in performance across competitors, changes in
laws and regulations affecting Science 37’s business and changes in
its capital structure, (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all, and
(vi) the potential adverse effects of the ongoing global COVID-19
pandemic. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of our
Annual Report on Form 10-K for the fiscal year ended December 31,
2021 filed with the U.S. Securities and Exchange Commission (the
“SEC”) on March 22, 2022 and in our other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Drew BustosScience
37PR@science37.com
INVESTOR RELATIONS:Caroline PaulScience 37 //
GilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024